Disperazol Pharma ApS: Financial statements 2025
CVR: 44265761
Source: annual report 2025, Danish Business Authority
09/08/2024 – 08/08/2025
Disperazol Pharma ApS (CVR 44265761) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -49,965 and a net result of DKK -41,573 compared with DKK 31,622 the year before. Equity in the 2025 report amounted to DKK 30,050. The solvency ratio was 60.4%.
- Gross Profit
- DKK -49,965
- Profit/Loss
- DKK -41,573
- Equity
- DKK 30,050
- Total Assets
- DKK 49,723
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | -50 t. | -42 t. | 30 t. | - |
| 2024 | - | 40 t. | 32 t. | 72 t. | - |
Official annual report
How creditworthy is Disperazol Pharma ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Disperazol Pharma ApS has published its annual report for 2024. Gross profit came to DKK 40,498, and the net result was DKK 31,622.
As of June 12, 2025, Carl Jörg Michael Graz is registered as adm. dir. of Disperazol Pharma ApS.
As of March 20, 2025, Carl Jörg Michael Graz has stepped down as adm. dir. of Disperazol Pharma ApS.
About Disperazol Pharma ApS
Disperazol Pharma ApS is a Danish company of the type Anpartsselskab based in Humlebæk, founded in 2023. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Carl Jörg Michael Graz. In 2025, the company reported a gross profit of DKK -49,965 and a net result of DKK -41,573 compared with DKK 31,622 the year before. Equity in the 2025 report amounted to DKK 30,050.